Targeted protein degradation of PDE4 shortforms by a novel proteolysis targeting chimera
The FEBS Journal · 2025-07 · 292 (13) · 3360-3377
DOI: 10.1111/febs.17359 ↗At a glance
Journal article in The FEBS Journal, published online on 2024-12-13. Written by Yuan Yan Sin and 16 co-authors. Institution: School of Cardiovascular and Metabolic Health, University of Glasgow, UK. Major MEDLINE topics: Cyclic Nucleotide Phosphodiesterases, Type 4, Proteolysis, Phosphodiesterase 4 Inhibitors. Cited 10 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY 4.0). Funded by: Medical Research Council, British Heart Foundation.
Abstract (original language)
Cyclic AMP (cAMP) has a crucial role in many vital cellular processes and there has been much effort expended in the discovery of inhibitors against the enzyme superfamily that degrades this second messenger, namely phosphodiesterases (PDEs). The journey of competitive PDE inhibitors to the clinic has been hampered by side effects profiles that have resulted from a lack of selectivity for subfamilies and individual isoforms because of high conservation of catalytic site sequences and structures. Here we introduce a proteolysis targeting chimera (PROTAC) that can specifically target a small subset of isoforms from the PDE4 family to send the enzyme for degradation at the proteasome by recruiting a ubiquitin E3 ligase into proximity with the PDE. We constructed our PDE4 PROTAC (KTX207) using a previously characterized PDE4 inhibitor, and we show that evolution of the compound into a PROTAC improves selectivity, potency and enables a long‐lasting effect even after the compound is removed from cells after a short treatment duration. Functionally, KTX207 is more effective at increasing cAMP, is 100 times more anti‐inflammatory, and is significantly better at reducing the growth in cancer cell models than the PDE4 inhibitor alone. Our study highlights the advantages of targeted degradation versus active‐site occupancy for PDE4 inhibition and discusses the potential of this novel pharmacological approach to improve the safety profile of PDE4 inhibition in the future.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Cardiovascular and Metabolic Health, University of Glasgow, UK.
- Faculty of Medicine, National Heart and Lung Institute, Imperial College London, UK.
- Graduate Program in Clinical Pathology, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Katalytic Therapeutics, San Diego, CA, USA.
- Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT) and Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
ORCID profiles: Yuan Yan Sin, Julia Gorelik, Pa Thai Yenchitsomanus, George S Baillie
Funding
- Medical Research Council
- British Heart Foundation
Cite
APA
Sin, Y. Y., Giblin, A., Judina, A., Rujirachaivej, P., Corral, L. G., Glennon, E., Tai, Z. X., Feng, T., Torres, E., Zorn, A., Gorelik, J., Kyurkchieva, E., Yenchitsomanus, P. T., Swindlehurst, C., Chan, K., Stirling, D., & Baillie, G. S. (2025). Targeted protein degradation of PDE4 shortforms by a novel proteolysis targeting chimera. The FEBS Journal, 292(13), 3360-3377. https://doi.org/10.1111/febs.17359
Vancouver
Sin YY, Giblin A, Judina A, Rujirachaivej P, Corral LG, Glennon E, et al. Targeted protein degradation of PDE4 shortforms by a novel proteolysis targeting chimera. The FEBS Journal. 2025;292(13):3360-3377. doi:10.1111/febs.17359
BibTeX
@article{Sin2025,
author = {Sin, Yuan Yan and Giblin, Aoife and Judina, Aleksandra and Rujirachaivej, Punchita and Corral, Laura G and Glennon, Eliza and Tai, Zhi Xian and Feng, Tian and Torres, Eduardo and Zorn, Alina and Gorelik, Julia and Kyurkchieva, Elka and Yenchitsomanus, Pa Thai and Swindlehurst, Cathy and Chan, Kyle and Stirling, David and Baillie, George S},
title = {Targeted protein degradation of PDE4 shortforms by a novel proteolysis targeting chimera},
journal = {The FEBS Journal},
year = {2025},
volume = {292},
number = {13},
pages = {3360--3377},
doi = {10.1111/febs.17359}
}
EUVIMED